A 72-year-old woman with a 15-year history of heart failure with reduced ejection fraction (EF 28%) is on lisinopril, metoprolol succinate, and spironolactone. Her recent echocardiogram shows no improvement in ejection fraction despite 6 months of optimal medical therapy. She remains symptomatic with NYHA Class III dyspnea. Her current medications are well-tolerated; serum creatinine is 1.2 mg/dL and potassium is 4.8 mEq/L. Her blood pressure is 110/70 mmHg and heart rate is 58/min. What is the most appropriate next addition to her regimen?

Explanation

## Clinical Context This patient has symptomatic HFrEF despite optimal triple therapy (ACE-I, beta-blocker, aldosterone antagonist) with adequate renal function and electrolytes. She requires escalation of evidence-based therapy to reduce symptoms and mortality. ## Guideline-Directed Medical Therapy (GDMT) in HFrEF **High-Yield:** The modern HFrEF treatment algorithm follows a stepwise approach: 1. **Foundational agents** (Class I): ACE-I/ARB, beta-blocker, aldosterone antagonist 2. **Fourth pillar** (Class IIa/IIb): ARNI (sacubitril/valsartan), SGLT2 inhibitor, ivabradine 3. **Adjunctive:** Hydralazine/nitrate (specific populations), digoxin (symptom relief only) **Key Point:** Sacubitril/valsartan (ARNI) is a **neprilysin inhibitor + ARB combination** that has superior mortality and morbidity benefits compared to ACE-I alone in HFrEF. It is recommended as a replacement for ACE-I/ARB in patients who remain symptomatic despite optimal therapy. ## Mechanism of ARNI (Sacubitril/Valsartan) ```mermaid flowchart TD A[Sacubitril/Valsartan]:::action --> B[Neprilysin inhibition]:::action A --> C[AT1 blockade]:::action B --> D[↑ Natriuretic peptides<br/>↑ Vasodilation<br/>↓ Fibrosis]:::outcome C --> E[↓ Angiotensin II<br/>↓ Vasoconstriction<br/>↓ Aldosterone]:::outcome D --> F[Improved HF outcomes]:::outcome E --> F ``` **Clinical Pearl:** Neprilysin breaks down natriuretic peptides (ANP, BNP), which are cardioprotective. By inhibiting neprilysin AND blocking angiotensin II, sacubitril/valsartan provides dual benefit: enhanced natriuretic peptide signaling + reduced RAAS activation. ## Evidence for ARNI in HFrEF | Trial/Guideline | Finding | Class | |---|---|---| | PARADIGM-HF | ARNI superior to enalapril; ↓ mortality 20%, ↓ HF hospitalization 21% | I | | 2022 AHA/ACC/HFSA Guidelines | ARNI recommended over ACE-I/ARB in HFrEF | IIa | | SGLT2i trials (DAPA-HF, EMPEROR-Reduced) | SGLT2i also recommended as fourth pillar | IIa | ## Why Option 1 (Increase Beta-Blocker Dose) Is Incorrect - The patient's heart rate is already 58/min, which is at target. Further dose escalation risks bradycardia, hypotension, and fatigue. - Beta-blockers reduce mortality but do NOT improve ejection fraction; they do not address the need for additional neurohormonal blockade. ## Why Option 2 (Add ARNI) Is Correct - **Replaces** lisinopril with sacubitril/valsartan (not added on top). - **Superior efficacy:** PARADIGM-HF demonstrated 20% mortality reduction and 21% reduction in HF hospitalizations compared to enalapril. - **Evidence-based:** Recommended by 2022 AHA/ACC/HFSA guidelines as next step in symptomatic HFrEF on triple therapy. - **Safe transition:** Lisinopril is stopped, then ARNI initiated after a washout period (24–48 hours) to avoid angioedema risk. ## Why Other Options Are Suboptimal **Option 3 (Add amlodipine):** Calcium channel blockers are NOT recommended in HFrEF (except diltiazem/verapamil in specific cases). Amlodipine does not provide mortality benefit and may worsen HF in some patients. **Option 4 (Add digoxin):** Digoxin provides symptomatic relief and may reduce HF hospitalizations but does NOT reduce mortality. It is reserved for HFrEF with concurrent atrial fibrillation or as last-line symptom management. It is NOT a modern GDMT agent.